Kadimastem, an Israeli biopharma venture, recently declared it was hoping to discuss with the U.S. Food and Drug Administration (FDA) its AstroRX cells experimental therapy, after demonstrating promising results with cohort AM of its Phase I/IIa clinical trials for...

The AMG Center for ALS at Mass General recently announced, along with Amylyx Pharmaceuticals, Inc., that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study. The team found that AMX0035 had a statistically significant slowing...

The ALS Never Surrender Foundation, a volunteer-based, non-profit organizations on a mission to cure Motor Neuron Disease and Amyotrophic Lateral Sclerosis (ALS) announced a $300,00 grant from the ALS Association to bring its ALS iNVOLVE/eNGAGE app to MND/ALS patient...

University of Arizona researchers have identified that increasing glucose, transformed into energy, can potentially give people afflicted with amyotrophic lateral sclerosis (ALS), improved mobility and a longer life. It is known that ALS patients experience...

A Southern Research Scientist’s early-stage work on potential new therapies for amyotrophic lateral sclerosis (ALS) is getting a push thanks to a grant from the Alabama Power Foundation. The researcher, Rita Cowell, PhD, Fellow and Chair of the Neuroscience Department...

A recent Phase 1 clinical trial involving the injection of human lateral sclerosis (ALS) was found safe and did not cause adverse effects even two years after the transplant. Study results were published in the journal Stem Cells Translational Medicine as reported...

Popular Links

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.